alexa Combination therapy with new targets in Type 2 diabetes: a review of available agents with a focus on pre-exercise adjustment.
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): McDonnell ME, McDonnell ME

Abstract Share this page

Abstract The current strategy for treating type 2 diabetes mellitus promotes combination therapy to address the 3 major defects in type 2 diabetes mellitus: (1) impaired peripheral glucose uptake (liver, fat, and muscle), (2) excessive hepatic glucose release (with glucagon excess), and (3) insufficient insulin secretion. Providers can prescribe medications that may have advantageous secondary effects in a patient-specific manner. Adjustment for exercise is generally necessary only with insulin and with medications that may allow insulin secretion despite decreasing glucose levels, such as sulfonylurea drugs. Recently, newer oral medications that address beta-cell dysfunction have been designed to avoid hypoglycemia and to "match" nutritional and non-nutritional needs more directly. Incorporating these agents into regimens will likely reduce hypoglycemia and therefore increase the safety and efficacy of exercise as both a treatment and cardiac monitoring strategy for patients with diabetes. This article was published in J Cardiopulm Rehabil Prev and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version